TABLE 2.

Fifteen surgical specimens from seven patients with invasive or metastatic pituitary tumors

Patient no.	Specimen	PCR: MGMT promoter			MGMT IHC
								Reviewer 1					Reviewer 2					Reviewer 3
				Methylated	Unmethylated	MGMT positive	Intensity	Total	MGMT positive	Intensity	Total	MGMT positive	Intensity	Total
1	A		X	3	1	4	3	1	4	3	2	5
2	A		X	1	2	3	Negative	0	0	1	1	2
	B		X	1	1	2	2	3	5	Negative	0	0
3	A		X	2	2	4	2	2	4	3	2	5
	B1		X	2	2	4	2	1	3	1	1	2
	C1		X	2	1	3	1	3	4	2	1	3
4	A		X	3	2	5	3	1	4	3	2	5
	B		X	2	1	3	2	3	5	3	2	5
5	A		X	1	1	2	Negative	0	0	1	1	2
	B		X	1	1	2	2	2	4	1	1	2
6	A1		X	3	1	4	3	1	4	3	2	5
	B1	N/A; necrotic specimen	N/A; necrotic specimen	N/A	N/A	Necrotic	N/A	N/A	Necrotic	N/A	N/A	Necrotic
	C1		X	3	2	5	3	1	4	3	2	5
7	A		X	1	1	2	1	2	3	Negative	0	0
	B		X	1	1	2	1	2	3	1	1	2

Methylation status of the MGMT promoter by MSP and MGMT immunoreactivity are shown. MGMT positive: 1 = <10% of cells positive in tumor; 2 = 10%–50%; 3 = > 50%. MGMT intensity: 1, faint; 2, moderate; 3, equivalent to positive controls. N/A, Not available.

¹Postradiation surgical specimen.